FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling

The epidermal growth factor receptor (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment. However, as with other targeted therapies, intrinsic/acquired resistance mechanisms limit efficacy. In...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Daly, C, Castanaro, C, Zhang, W, Zhang, Q, Wei, Y, Ni, M, Young, T M, Zhang, L, Burova, E, Thurston, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290037/
https://ncbi.nlm.nih.gov/pubmed/27345413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.216
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados